HC Wainwright Boosts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $33.00


Share on StockTwits

Collegium Pharmaceutical (NASDAQ:COLL) had its target price lifted by HC Wainwright from $29.00 to $33.00 in a research note issued to investors on Monday morning, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Needham & Company LLC restated a buy rating on shares of Collegium Pharmaceutical in a research report on Tuesday, December 29th. BidaskClub downgraded shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Thursday, October 22nd. Finally, Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a hold rating to a strong sell rating in a report on Tuesday, January 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. Collegium Pharmaceutical presently has a consensus rating of Buy and an average price target of $28.86.

Shares of NASDAQ COLL opened at $21.83 on Monday. The firm’s 50-day moving average price is $19.56 and its 200-day moving average price is $18.89. The company has a current ratio of 1.08, a quick ratio of 1.01 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $754.93 million, a price-to-earnings ratio of 44.55, a P/E/G ratio of 0.65 and a beta of 1.27. Collegium Pharmaceutical has a 12-month low of $13.00 and a 12-month high of $25.59.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.58). The business had revenue of $77.40 million for the quarter, compared to analysts’ expectations of $77.39 million. Collegium Pharmaceutical had a net margin of 5.71% and a return on equity of 12.64%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.18) earnings per share. On average, equities analysts predict that Collegium Pharmaceutical will post 0.92 EPS for the current fiscal year.

In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 16,042 shares of the company’s stock in a transaction dated Thursday, January 7th. The shares were sold at an average price of $22.00, for a total value of $352,924.00. Following the transaction, the chief technology officer now directly owns 114,755 shares in the company, valued at approximately $2,524,610. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Alison B. Fleming sold 5,967 shares of the company’s stock in a transaction dated Thursday, December 3rd. The stock was sold at an average price of $19.24, for a total transaction of $114,805.08. Following the completion of the transaction, the chief technology officer now owns 111,419 shares in the company, valued at $2,143,701.56. The disclosure for this sale can be found here. 8.08% of the stock is owned by corporate insiders.

Hedge funds have recently modified their holdings of the business. Advisor Group Holdings Inc. lifted its position in shares of Collegium Pharmaceutical by 104.5% in the 2nd quarter. Advisor Group Holdings Inc. now owns 1,395 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 713 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 332.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock worth $65,000 after purchasing an additional 2,392 shares during the period. Great West Life Assurance Co. Can lifted its position in shares of Collegium Pharmaceutical by 58.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,614 shares of the specialty pharmaceutical company’s stock worth $99,000 after purchasing an additional 1,340 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of Collegium Pharmaceutical by 539.5% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,892 shares of the specialty pharmaceutical company’s stock worth $164,000 after purchasing an additional 6,658 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter worth approximately $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.

Featured Story: Retained Earnings

The Fly

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.